Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia

Exclusion Criteria

• •1. The patient has a decrease in the PANSS Total Score at Baseline compared with the Total Score at Screening.
• •2. Patient who recently participated in another interventional clinical study with an Investigational Medicinal Product.
• •3. The patient has uncontrolled abnormality which may impact the ability of the patient to participate or potentially confound the study results.
• •4. The patient has a history of severe head injury, traumatic brain injury, myocardial infarction or stroke.
• •5. The patient has a moderate or severe substance use disorder for alcohol or other substances of abuse except nicotine or caffeine.
• •6. The patient is pregnant or lactating or intending to become pregnant or intending to donate ova.
• •7. The patient has a history of or known personality disorder or other psychiatric disorder that, in the opinion of the Investigator, would interfere with participation in the study.
• •8. The patient is considered by the Investigator to be at imminent risk of suicide or injury to self or others.
• •9. The patient has chronic movement disorder that may interfere with the interpretation of study results.
• •10. The patient has any existing or previous history of cancer or has newly diagnosed diabetes.
• •11. The patient has long QT syndrome or is under treatment with antiarrhythmic drugs.
• •12. The patient is considered to be treatment resistant. .
• •13. The patient has received electroconvulsive therapy.
• •14. The patient has any laboratory values outside the normal range that are considered by the Investigator to be clinically significant at Screening.